lusutrombopag and Body-Weight

lusutrombopag has been researched along with Body-Weight* in 1 studies

Trials

1 trial(s) available for lusutrombopag and Body-Weight

Article	Year
Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects. Clinical pharmacokinetics, 2016, Volume: 55, Issue:11 The aim of this study was to develop a population pharmacokinetic (PK)/pharmacodynamic (PD) model for describing plasma lusutrombopag concentrations and platelet response following oral lusutrombopag dosing and for evaluating covariates in the PK/PD profiles.. A population PK/PD model was developed using a total of 2539 plasma lusutrombopag concentration data and 1408 platelet count data from 78 healthy adult subjects following oral single and multiple (14-day once-daily) dosing. Covariates in PK and PK/PD models were explored for subject age, body weight, sex, and ethnicity.. A population PK/PD model was developed for lusutrombopag and shown to provide good prediction for the PK/PD profiles. The model could be used as a basic PK/PD model in the drug development of lusutrombopag. Topics: Adult; Age Factors; Area Under Curve; Body Weight; Cinnamates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Healthy Volunteers; Humans; Male; Middle Aged; Models, Biological; Racial Groups; Receptors, Thrombopoietin; Sex Factors; Thiazoles; White People	2016

Article

Year

Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects.

Clinical pharmacokinetics, 2016, Volume: 55, Issue:11

The aim of this study was to develop a population pharmacokinetic (PK)/pharmacodynamic (PD) model for describing plasma lusutrombopag concentrations and platelet response following oral lusutrombopag dosing and for evaluating covariates in the PK/PD profiles.. A population PK/PD model was developed using a total of 2539 plasma lusutrombopag concentration data and 1408 platelet count data from 78 healthy adult subjects following oral single and multiple (14-day once-daily) dosing. Covariates in PK and PK/PD models were explored for subject age, body weight, sex, and ethnicity.. A population PK/PD model was developed for lusutrombopag and shown to provide good prediction for the PK/PD profiles. The model could be used as a basic PK/PD model in the drug development of lusutrombopag.

Topics: Adult; Age Factors; Area Under Curve; Body Weight; Cinnamates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Healthy Volunteers; Humans; Male; Middle Aged; Models, Biological; Racial Groups; Receptors, Thrombopoietin; Sex Factors; Thiazoles; White People

2016